Profile of oral manifestations of graft versus host disease

Julia Rahal de  Camargo; Halina Grossmann-Pereira; Rafael Zancan  Mobile; Cassius Carvalho Torres-Pereira; Juliana Lucena Schussel

doi:10.5327/2525-5711.322

Autores/as

Julia Rahal de Camargo Universidade Federal do Paraná, Department of Stomatology – Curitiba (PR), Brazil. https://orcid.org/0000-0002-2837-0754
Halina Grossmann-Pereira Universidade Federal do Paraná, Post-Graduate Program in Dentistry – Curitiba (PR), Brazil. https://orcid.org/0009-0000-5041-631X
Rafael Zancan Mobile Universidade Federal do Paraná, Post-Graduate Program in Dentistry – Curitiba (PR), Brazil. https://orcid.org/0000-0002-8603-2614
Cassius Carvalho Torres-Pereira Universidade Federal do Paraná, Department of Stomatology – Curitiba (PR), Brazil. https://orcid.org/0000-0001-8049-7544
Juliana Lucena Schussel Universidade Federal do Paraná, Department of Stomatology – Curitiba (PR), Brazil. https://orcid.org/0000-0001-5204-0782

DOI:

https://doi.org/10.5327/2525-5711.322

Palabras clave:

Hematopoietic stem cell transplantation, Graft-versus-host disease, Oral manifestations

Resumen

Objective: The objective of this cohort study was to evaluate patients previously diagnosed with oral lesions associated GVHD, aiming to characterize and describe the primary clinical presentations observed. Methods: A retrospective analysis of medical and dental records, alongside a photographic review, was conducted to assess the oral manifestations of GVHD in these patients. Results: The evaluation of medical records shows that GVHD affected more males (58.4%); The most affected age group was 21-50 years (55.6%); The most frequent lesion was hyperkeratotic plaque (76.4). The most common underlying disease was Fanconi Anemia (FA) representing 54.2%. Of these, 5.1% developed some malignant neoplasm, confirming the fact that patients with FA have a marked predisposition to carcinomas. Conclusion: It is evident that GVHD manifests itself in different ways in the oral cavity, therefore, knowing the clinical presentation of GVHD becomes important to determine the most appropriate treatment and to differentiate it from lesions with malignant potential.

Citas

Bazinet A, Popradi G. A general practitioner's guide to hematopoietic stem-cell transplantation. Curr Oncol. 2019;26(3):187-91. https://doi.org/10.3747/co.26.5033

Pinto GR, Sarmento VA, Carvalho-Filho PC, Fortuna VA, Costa RS, Conceição RR, et al. Gene expression profile of chronic oral graft-versus-host disease. PLoS One. 2022;17(4):e0267325. https://doi.org/10.1371/journal.pone.0267325

Scaraficci AC, Fernandes PM, Alves FA, Schimidt Filho J, Jaguar GC. Oral manifestations of graft-versus-host disease in patients submitted to allogeneic hematopoietic stem cell transplantation: the experience of a Brazilian Cancer Center. Support Care Cancer. 2022;30(1):567-73. https://doi.org/10.1007/s00520-021-06349-9

Kim EJ, Kim N, Cho SG. The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. Exp Mol Med. 2013;45(1):e2. https://doi.org/10.1038/emm.2013.2

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1. https://doi.org/10.1016/j.bbmt.2014.12.001

Piccin A, Tagnin M, Vecchiato C, Al-Khaffaf A, Beqiri L, Kaiser C, et al. Graft-versus-host disease (GvHD) of the tongue and of the oral cavity: a large retrospective study. Int J Hematol. 2018;108(6):615-21. https://doi.org/10.1007/s12185-018-2520-5

Margaix-Munoz M, Bagán JV, Jiménez Y, Sarrión MG, Poveda-Roda R. Graft-versus-host disease affecting oral cavity. A review. J Clin Exp Dent. 2015;7(1):e138-45. https://doi.org/10.4317/jced.51975

Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21(6):984-99. https://doi.org/10.1016/j.bbmt.2015.02.025

Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, Bagan JV, González-Moles MA, Kerr AR, et al. Oral potentially malignant disorders: a consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. 2021;27(8):1862-80. https://doi.org/10.1111/odi.13704

Meier JKH, Wolff D, Pavletic S, Greinix H, Gosau M, Bertz H, et al. Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Investig. 2011;15(2):127-39. https://doi.org/10.1007/s00784-010-0450-6

Leidens N, Ballardin BS, Leal GA, Araújo AMM, Sessenta-Junior CF, Torres-Pereira CC, et al. Graft-versus-host disease and herpes simplex virus oral injuries in onco-hematological patient: case report. Spec Care Dentist. 2022;42(1):91-6. https://doi.org/10.1111/scd.12640

Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW. Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis. 2013;19(4):327-46. https://doi.org/10.1111/odi.12028

Dean D, Sroussi H. Oral chronic graft-versus-host disease. Front Oral Health. 2022;3:903154. https://doi.org/10.3389/froh.2022.903154

Janowiak-Majeranowska A, Osowski J, Mikaszewski B, Majeranowski A. Secondary oral cancer after systemic treatment of hematological malignancies and oral GVHD: a systematic review. Cancers (Basel). 2022;14(9):2175. https://doi.org/10.3390/cancers14092175

Kutler DI, Patel KR, Auerbach AD, Kennedy J, Lach FP, Sanborn E, et al. Natural history and management of Fanconi anemia patients with head and neck cancer: a 10-year follow-up. Laryngoscope. 2016;126(4):870-9. https://doi.org/10.1002/lary.25726

Furquim CP, Pivovar A, Amenábar JM, Bonfim C, Torres-Pereira CC. Oral cancer in Fanconi anemia: review of 121 cases. Crit Rev Oncol Hematol. 2018;125:35-40. https://doi.org/10.1016/j.critrevonc.2018.02.013

Amenábar JM, Torres-Pereira CC, Tang KD, Punyadeera C. Two enemies, one fight: an update of oral cancer in patients with Fanconi anemia. Cancer. 2019;125(22):3936-46. https://doi.org/10.1002/cncr.32435